Wikisage, the free encyclopedia of the second generation, is digital heritage
XR-topiramate: Difference between revisions
Jump to navigation
Jump to search
(cat) |
mNo edit summary |
||
| Line 4: | Line 4: | ||
[http://www.epilepsybehavior.com/article/S1525-5050(16)00057-3/pdf Clinical utility of topiramate extended-release capsules (USL255): Bioequivalence of USL255 sprinkled and intact capsule in healthy adults and an in vitro evaluation of sprinkle delivery via enteral feeding tubes] | [http://www.epilepsybehavior.com/article/S1525-5050(16)00057-3/pdf Clinical utility of topiramate extended-release capsules (USL255): Bioequivalence of USL255 sprinkled and intact capsule in healthy adults and an in vitro evaluation of sprinkle delivery via enteral feeding tubes] | ||
<references/> | |||
[[Category:Anticonvulsants]] | |||
[[Category: | |||
Latest revision as of 23:53, 11 December 2016
Qudexy XR was approved by FDA on March 2014. It is effective on partial onset seisure once daily schedule[1]